Abstract
Nanotechnology has many applications in disorders of the eye, which could be included under the heading of nano-ophthalmology. These include drug delivery, study of pathomechanism of eye diseases, regeneration of the optic nerve, and counteracting neovascularization involved in some degenerative disorders. Nanoparticles enable delivery of ocular drugs to specific target sites, and results to date strongly suggest that ophthalmology will benefit enormously from the use of this nanometric scale technology.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm. Pharmacol 2005;57:1555–63.
Birch DG, Liang FQ. Age-related macular degeneration: a target for nanotechnology derived medicines. Int J Nanomedicine 2007;2:65–77.
Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003;44:3562–9.
de Kozak Y, Andrieux K, Villarroya H et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004;34:3702–12.
de Salamanca AE, Diebold Y, Calonge M et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci 2006; 47:1416–25.
Delgado D, Del Pozo-RodrÃguez A, SolinÃs MA, et al. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X linked juvenile retinoschisis. Hum Gene Ther 2012 Feb 1. [Epub ahead of print]
Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010;29:596–609.
Farjo R, Skaggs J, Quiambao AB, et al. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 2006;1:e38.
Li H, Tran V, Hu Y, et al. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp Eye Res 2006;83:824–833.
Marano RJ, Toth I, Wimmer N, et al. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005;12:1544–50.
Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008;68:513–25.
Patil S, Reshetnikov S, Haldar MK, et al. Surface-Derivatized Nanoceria with Human Carbonic Anhydrase II Inhibitors and Fluorophores: A Potential Drug Delivery Device. J Phys Chem C 111 2007;24:8437–42.
Vandervoort J, Ludwig A. Ocular drug delivery: nanomedicine applications. Nanomedicine 2007;2:11–21.
Vega E, Egea MA, Valls O, et al. Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration. J Pharm Sci 2006;95:2393–405.
Yuan X, Li H, Yuan Y. Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydr Polym 2006;65;337–45.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jain, K.K. (2012). Nano-ophthalmology. In: The Handbook of Nanomedicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-983-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-61779-983-9_13
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-982-2
Online ISBN: 978-1-61779-983-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)